- Home
- CB vs VRTX Comparison
CB vs VRTX Comparison
Compare CB & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | VRTX |
|---|---|---|
| Founded | 1985 | 1989 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.7B | 115.7B |
| IPO Year | 1995 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CB | VRTX |
|---|---|---|
| Price | $327.52 | $455.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 27 |
| Target Price | $332.00 | ★ $526.79 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | 13.13 | ★ 836.54 |
| EPS | ★ 25.68 | 15.32 |
| Revenue | ★ $59,402,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | N/A | $10.79 |
| Revenue Next Year | $5.31 | $10.14 |
| P/E Ratio | ★ $12.98 | $30.10 |
| Revenue Growth | 6.54 | ★ 46.20 |
| 52 Week Low | $264.10 | $362.50 |
| 52 Week High | $345.67 | $519.68 |
Technical Indicators
Market Signals| Indicator | CB | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 42.72 |
| Support Level | $322.43 | $455.62 |
| Resistance Level | $335.60 | $465.98 |
| Average True Range (ATR) | 5.53 | 13.17 |
| MACD | -1.36 | -2.82 |
| Stochastic Oscillator | 19.97 | 13.47 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.